Provectus Biopharmaceuticals is developing advanced

New Post Public Reply Private Reply Replies (0) Message Board

Jan 7, 2015 at 10:36 AM

Provectus Biopharmaceuticals is
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects

PV-10

An Investigational Drug for Cancer

PV-10 for Cutaneous, Recurrent and Metastatic Melanoma
A Phase 2 clinical trial has been successfully completed, and a protocol for a Phase 3 clinical trial has been submitted to the FDA.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of metastatic melanoma.
PV-10 for Locally Metastatic Liver Cancer
An expanded Phase I clinical trial is currently underway.
PV-10 has Received Orphan Drug Designation from the US FDA for the treatment of liver cancer.
PV-10 for Recurrent Breast Cancer
A Phase I clinical trial has been completed. In conjunction with Moffitt Cancer Center research, further development is currently being assessed.
A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
The Moffitt Cancer Center is performing a mechanism of action study to examine the systemic immune response induced by intralesional PV-10 injections.

PH-10

An Investigational Drug for Psoriasis and Atopic Dermatitis

PH-10 for Psoriasis
A Phase 2c randomized clinical trial has been successfully completed.
A Phase 2b clinical trial has been successfully completed.
PH-10 for Atopic Dermatitis
A Phase 2 clinical trial has been successfully completed.
PH-10's mechanism of action is currently being examined.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

IN THE MEDIA
January 7, 2015
Provectus to Be Inaugural Member of the AAPI Global Clinical Trial Network
January 6, 2015
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study
December 30, 2014
Promising Strategy for Advanced Melanoma: Intralesional Therapies Plus Systemic Immunotherapies
December 19, 2014
Decision-Plus Interviews Provectus CFO and COO Peter Culpepper
December 5, 2014
Oncologists examine efficacy of rose bengal against cancer
December 5, 2014
Study Finds Combined PV-10 And Immune Checkpoint Inhibitors Efficient In Melanoma Treatment
December 4, 2014
Rose Bengal and Co-Inhibitory Blockade Improve Anti-Tumor Immunity, Melanoma Regression
December 2, 2014
PV-10 Data Published; Phase 3 Protocol Published
November 20, 2014
PV-10 and checkpoint inhibitor enhance melanoma regression
November 19, 2014
Combination of PV-10 and checkpoint inhibitor boosts melanoma tumour regression
November 18, 2014
Melanoma shows improved regression with combination of PV-10 and checkpoint inhibitor
November 17, 2014
Provectus Biopharmaceuticals Presents PV-10 Data
November 17, 2014
It may just be do or dye time for cancer biotechs
November 14, 2014
Eye-dye melanoma try: Provectus phase III plan for injectable with FDA
November 12, 2014
Provectus Biopharmaceuticals Issues PV-10 Phase 3 Melanoma Protocol to FDA
November 10, 2014
Oncology News Reports on Melanoma Research Presented at ESMO
November 6, 2014
Webcast: Conference Call November 6, 2014 4:00 PM EDT
November 3, 2014
PV-10 in Metastatic Melanoma: Rapid Responses Led Phase 3
November 3, 2014
Investigational Agent For Metastatic Melanoma Shows Rapid Complete Responses In High Proportion Of Patients In Early Trials
October 30, 2014
A New Cancer Drug Worked In Over 50% Of Patients In A Phase II Trial
more...
PRESS RELEASES
December 23, 2014
Provectus Biopharmaceuticals' Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Markers of Psoriasis Now Available Online
December 22, 2014
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment
December 17, 2014
Provectus Biopharmaceuticals To Sponsor American Association of Physicians of Indian Origin
November 14, 2014
Provectus Biopharmaceuticals Extends Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-THINK Pharmaceutical Co., Ltd
November 13, 2014
Provectus Biopharmaceuticals' Protocol for Phase 3 Study Of PV-10 As Treatment for Melanoma Now Available Online
November 10, 2014
Provectus Biopharmaceuticals PV-10 Data Presented at SITC 29TH Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. Reports Third Quarter Results
November 6, 2014
Provectus Biopharmaceuticals Submits PV-10 Phase 3 Melanoma Protocol to FDA
November 6, 2014
Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting
November 6, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call Today at 4 PM Eastern Standard Time
October 31, 2014
Provectus Biopharmaceuticals, Inc. to Hold Quarterly Conference Call on Thursday, November 6, 2014
October 28, 2014
Provectus' Intralesional PV-10 Clinical Data Published in the Annals of Surgical Oncology
October 16, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the 2014 International Congress of the Society for Melanoma Research
October 15, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
October 14, 2014
INC Research Signs Agreement to Perform FDA Due Diligence Audit of Regulatory Documents for Provectus Biopharmaceuticals
October 8, 2014
Provectus' Intralesional PV-10 Clinical Data to Be Presented to the Eurasian Federation of Oncology
October 7, 2014
Provectus' Intralesional PV-10 to Be Presented at the 2014 Beijing International Melanoma Congress
September 29, 2014
Provectus Biopharmaceuticals Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10
September 24, 2014
Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available for European Society for Medical Oncology 2014 Congress
September 23, 2014
Provectus' Intralesional PV-10 and Co-Inhibitory Blockade Data to Be Presented at SITC 29th Annual Meeting
more...

Copyright (c) 2002-2014 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!

Alway's searching for winners'

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

VISTAR Oakland Workers Join Teamsters for Unity

Warehouse Workers Break Free from the Shackles Ever had that feeling, where enough is enough? That's where 37 warehouse workers at VISTAR find themselves, shaking off the dust and signing up with Teamsters Local 853. This ain't just a fleeting wind of change; it's the whole damn storm. Turning Points and Union Victories Think about it. This move by the VISTAR warehouse...

Nomada Fund Launches: A Game-Changer in New Media

Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Ryan Stills: Vegan Powerlifter Defies Odds, Wins Sixth World Title

Ryan Stills: A Comeback Story for the Ages Ryan Stills isn't just lifting weights; he's lifting the entire perception of what's possible after a heavy surgical setback. We're talking about a guy who stared down a hemi-shoulder replacement—a career ender for many—and came out the other side with a whole new set of gold medals. Two years ago, some might have written him...

Taiwan Excellence Sparks Smart Automotive Innovation at SEMA

Taiwan's making waves, folks, and it's not your everyday splash in the automotive pool. At SEMA 2026, Taiwan Excellence Pavilion is the place to be with its array of intelligent automotive solutions. This ain't just your run-of-the-mill car show gimmickry—it's the future rolling in real-time. Driving Innovation: From Components to Smart Systems The name of the game is...

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

D2L Ventures into Vietnam with Van Lang Alliance

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Community Heritage Financial Declares Q3 2026 Dividend

Dividend Declared Amidst Challenging Times There's nothing quite like the ringing of a cash register, and for Community Heritage Financial, Inc. (OTCID: CMHF), that's what an $0.08 per share dividend feels like. Declared for the third quarter of 2026, this payout is set to line the pockets of shareholders who made the cut by October 30, 2026. The folks waiting for their...

Kenneth Smith Takes Helm for Trends Int’l Expansion

Tired of the Same Old Leadership Shuffle? Here Comes Kenneth Smith Look, I’ve seen my share of execs come and go, usually dragging the same old briefcase of stale ideas. But Kenneth Smith stepping up as CEO of Trends International? Now that’s got some real teeth to it. Come May 2026, he’s the guy at the helm, and he's got one hell of a to-do list. Smith's Roadmap: A...

Standex's New Financial Lead: Stoddard Takes Helm

New Financial Captain Aboard Standex's Ship Alright, here's something that'll have investors nodding along with interest: Standex International has just named Samantha L. Stoddard as their incoming Chief Financial Officer and Treasurer, effective December 1, 2026. Now, Standex isn't some scrappy upstart. We're talking about a veteran manufacturer intricately working...